靶向HER2的抗体药物偶联物治疗非小细胞肺癌研究进展
Advances in the Study of Antibody-Drug Conjugates Targeting HER2 for the Treatment of Non-Small Cell Lung Cancer
DOI: 10.12677/acm.2025.1541021, PDF,   
作者: 黄 熙：成都中医药大学医学与生命科学学院，四川 成都；杨 丽：宜宾市第一人民医院肿瘤放疗科，四川 宜宾
关键词: 抗体药物偶联物；人表皮生长因子受体2；非小细胞肺癌；Antibody-Drug Coupler； Human Epidermal Growth Factor Receptor 2； Non-Small Cell Lung Cancer
摘要: 原发性肺癌是目前最常见的癌症之一，也是全球癌症相关死亡的主要原因。人表皮生长因子受体2 (HER2)作为一种与非小细胞肺癌预后密切相关的靶点，已成为近年来的研究热点。其中抗体耦联药物这一种新兴的肿瘤治疗手段，作为一类选择性的递送细胞毒物到肿瘤细胞的治疗化合物，为HER2突变型NSCLC的治疗带来了新的希望，克服了传统的化疗药物和单克隆抗体治疗的局限性。本篇综述了ADC药物在HER2阳性的非小细胞肺癌治疗领域的最新进展，探讨了其疗效和安全性的潜力，旨在为未来临床治疗过程中提供参考。
Abstract: Primary lung cancer is one of the most common cancers and the leading cause of cancer-related deaths worldwide. Human epidermal growth factor receptor 2 (HER2), as a target closely related to the prognosis of non-small cell lung cancer, has become a hot research topic in recent years. Among them, antibody-drug conjugates (ADCs), an emerging tumor therapy, as a class of therapeutic compounds that selectively deliver cytotoxic agents to tumor cells, have brought new hope for the treatment of HER2-mutant NSCLC, overcoming the limitations of traditional chemotherapeutic agents and monoclonal antibody therapy. In this review, we present the latest advances in the field of ADC drugs in the treatment of HER2-positive NSCLC and discuss their potential in terms of efficacy and safety, aiming to provide a reference for the future clinical treatment process.
文章引用：黄熙, 杨丽. 靶向HER2的抗体药物偶联物治疗非小细胞肺癌研究进展[J]. 临床医学进展, 2025, 15(4): 984-991. https://doi.org/10.12677/acm.2025.1541021

参考文献

[1] Howlader, N., Forjaz, G., Mooradian, M.J., Meza, R., Kong, C.Y., Cronin, K.A., et al. (2020) The Effect of Advances in Lung-Cancer Treatment on Population Mortality. New England Journal of Medicine, 383, 640-649. [Google Scholar] [CrossRef] [PubMed]
[2] Shaw, A.T., Ou, S.I., Bang, Y., Camidge, D.R., Solomon, B.J., Salgia, R., et al. (2014) Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer. New England Journal of Medicine, 371, 1963-1971. [Google Scholar] [CrossRef] [PubMed]
[3] Planchard, D., Smit, E.F., Groen, H.J.M., Mazieres, J., Besse, B., Helland, Å., et al. (2017) Dabrafenib Plus Trametinib in Patients with Previously Untreated BRAFV600E-Mutant Metastatic Non-Small-Cell Lung Cancer: An Open-Label, Phase 2 Trial. The Lancet Oncology, 18, 1307-1316. [Google Scholar] [CrossRef] [PubMed]
[4] Solomon, B.J., Mok, T., Kim, D., Wu, Y., Nakagawa, K., Mekhail, T., et al. (2014) First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine, 371, 2167-2177. [Google Scholar] [CrossRef] [PubMed]
[5] Hotta, K., Aoe, K., Kozuki, T., Ohashi, K., Ninomiya, K., Ichihara, E., et al. (2018) A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 13, 273-279. [Google Scholar] [CrossRef] [PubMed]
[6] Wang, Y., Zhang, S.J., Wu, F.Y., Zhao, J., Li, X.F., Zhao, C., et al. (2018) Outcomes of Pemetrexed-Based Chemotherapies in HER2-Mutant Lung Cancers. BMC Cancer, 18, Article No. 326. [Google Scholar] [CrossRef] [PubMed]
[7] Arcila, M.E., Chaft, J.E., Nafa, K., Roy-Chowdhuri, S., Lau, C., Zaidinski, M., et al. (2012) Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas. Clinical Cancer Research, 18, 4910-4918. [Google Scholar] [CrossRef] [PubMed]
[8] Cho, H.-S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelli, S.B., Denney, D.W., et al. (2003) Structure of the Extracellular Region of HER2 Alone and in Complex with the Herceptin Fab. Nature, 421, 756-760. [Google Scholar] [CrossRef] [PubMed]
[9] Matsuoka, T. (2015) Recent Advances in the HER2 Targeted Therapy of Gastric Cancer. World Journal of Clinical Cases, 3, 42-51. [Google Scholar] [CrossRef] [PubMed]
[10] Wang, X.H., Batty, K.M., Crowe, P.J., Goldstein, D. and Yang, J.-L. (2015) The Potential of PanHER Inhibition in Cancer. Frontiers in Oncology, 5, Article 2. [Google Scholar] [CrossRef] [PubMed]
[11] Schlessinger, J. (2004) Common and Distinct Elements in Cellular Signaling via EGF and FGF Receptors. Science, 306, 1506-1507. [Google Scholar] [CrossRef] [PubMed]
[12] Milgram, B.C., Borrelli, D.R., Brooijmans, N., Henderson, J.A., Hilbert, B.J., Huff, M.R., et al. (2025) Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer. Journal of Medicinal Chemistry, 68, 2403-2421. [Google Scholar] [CrossRef] [PubMed]
[13] Rolfo, C. and Russo, A. (2020) HER2 Mutations in Non–Small Cell Lung Cancer: A Herculean Effort to Hit the Target. Cancer Discovery, 10, 643-645. [Google Scholar] [CrossRef] [PubMed]
[14] Cen, S., Liu, Z., Pan, H. and Han, W. (2021) Clinicopathologic Features and Treatment Advances in Cancers with HER2 Alterations. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1876, Article 188605. [Google Scholar] [CrossRef] [PubMed]
[15] Li, B.T., Shen, R., Buonocore, D., Olah, Z.T., Ni, A., Ginsberg, M.S., et al. (2018) Ado-Trastuzumab Emtansine for Patients with HER2-Mutant Lung Cancers: Results from a Phase II Basket Trial. Journal of Clinical Oncology, 36, 2532-2537. [Google Scholar] [CrossRef] [PubMed]
[16] Meric-Bernstam, F., Johnson, A.M., Dumbrava, E.E.I., Raghav, K., Balaji, K., Bhatt, M., et al. (2019) Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clinical Cancer Research, 25, 2033-2041. [Google Scholar] [CrossRef] [PubMed]
[17] Peters, S., Loi, S., André, F., Chandarlapaty, S., Felip, E., Finn, S.P., et al. (2024) Antibody-Drug Conjugates in Lung and Breast Cancer: Current Evidence and Future Directions—A Position Statement from the ETOP IBCSG Partners Foundation. Annals of Oncology, 35, 607-629. [Google Scholar] [CrossRef] [PubMed]
[18] Passaro, A., Jänne, P.A. and Peters, S. (2023) Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies. Journal of Clinical Oncology, 41, 3747-3761. [Google Scholar] [CrossRef] [PubMed]
[19] Singh, A.P. and Shah, D.K. (2019) A “Dual” Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC. Journal of Pharmaceutical Sciences, 108, 2465-2475. [Google Scholar] [CrossRef] [PubMed]
[20] 朱雪亚, 李泽运, 田鑫, 等. 单克隆抗体药物药代动力学特征、分析方法以及体内分析方法学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(1): 113-120.
[21] 郭建军, 王丽丽, 张琪, 等. 单克隆抗体药物的药代动力学研究进展[J]. 中国药理学通报, 2016, 32(2): 172-176.
[22] 高华晔, 李娴静, 钟书霖, 等. 单克隆抗体药物及抗体偶联药物的药代动力学研究进展[J]. 药学与临床研究, 2019, 27(3): 212-215.
[23] Kamath, A.V. and Iyer, S. (2014) Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates. Pharmaceutical Research, 32, 3470-3479. [Google Scholar] [CrossRef] [PubMed]
[24] Sauerborn, M. and van Dongen, W. (2014) Practical Considerations for the Pharmacokinetic and Immunogenic Assessment of Antibody—Drug Conjugates. BioDrugs, 28, 383-391. [Google Scholar] [CrossRef] [PubMed]
[25] Drago, J.Z., Modi, S. and Chandarlapaty, S. (2021) Unlocking the Potential of Antibody—Drug Conjugates for Cancer Therapy. Nature Reviews Clinical Oncology, 18, 327-344. [Google Scholar] [CrossRef] [PubMed]
[26] Beck, A., Goetsch, L., Dumontet, C. and Corvaïa, N. (2017) Strategies and Challenges for the Next Generation of Antibody—Drug Conjugates. Nature Reviews Drug Discovery, 16, 315-337. [Google Scholar] [CrossRef] [PubMed]
[27] Fu, Z., Li, S., Han, S., Shi, C. and Zhang, Y. (2022) Antibody Drug Conjugate: The “Biological Missile” for Targeted Cancer Therapy. Signal Transduction and Targeted Therapy, 7, Article No. 93. [Google Scholar] [CrossRef] [PubMed]
[28] Lyon, R.P., Bovee, T.D., Doronina, S.O., Burke, P.J., Hunter, J.H., Neff-LaFord, H.D., et al. (2015) Reducing Hydrophobicity of Homogeneous Antibody—Drug Conjugates Improves Pharmacokinetics and Therapeutic Index. Nature Biotechnology, 33, 733-735. [Google Scholar] [CrossRef] [PubMed]
[29] He, J., Yu, S., Yee, S., Kaur, S. and Xu, K. (2018) Characterization of in Vivo Biotransformations for Trastuzumab Emtansine by High-Resolution Accurate-Mass Mass Spectrometry. mAbs, 10, 960-967. [Google Scholar] [CrossRef] [PubMed]
[30] Iwama, E., Zenke, Y., Sugawara, S., Daga, H., Morise, M., Yanagitani, N., et al. (2022) Trastuzumab Emtansine for Patients with Non-Small Cell Lung Cancer Positive for Human Epidermal Growth Factor Receptor 2 Exon-20 Insertion Mutations. European Journal of Cancer, 162, 99-106. [Google Scholar] [CrossRef] [PubMed]
[31] Ogitani, Y., Hagihara, K., Oitate, M., Naito, H. and Agatsuma, T. (2016) Bystander Killing Effect of Ds-8201a, a Novel Anti‐Human Epidermal Growth Factor Receptor 2 Antibody—Drug Conjugate, in Tumors with Human Epidermal Growth Factor Receptor 2 Heterogeneity. Cancer Science, 107, 1039-1046. [Google Scholar] [CrossRef] [PubMed]
[32] Son, J., Jang, J., Beyett, T.S., Eum, Y., Haikala, H.M., Verano, A., et al. (2022) A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung Cancer. Cancer Research, 82, 1633-1645. [Google Scholar] [CrossRef] [PubMed]
[33] Goto, K., Goto, Y., Kubo, T., et al. (2023) Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results from the Randomized, Phase II DESTINY-Lung02 Trial. Journal of Clinical Oncology, 41, 4852-4863.
[34] Keam, S.J. (2020) Trastuzumab Deruxtecan: First Approval. Drugs, 80, 501-508. [Google Scholar] [CrossRef] [PubMed]
[35] Li, B.T., Michelini, F., Misale, S., Cocco, E., Baldino, L., Cai, Y., et al. (2020) HER2—Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. Cancer Discovery, 10, 674-687. [Google Scholar] [CrossRef] [PubMed]
[36] Halani, V., Sharayah, A., Beck, B. and Patolia, S. (2024) “New Targets in Non-Small-Cell Lung Cancer”—RET, HER2, and KRAS. American Journal of Respiratory and Critical Care Medicine, 209, 748-750. [Google Scholar] [CrossRef] [PubMed]
[37] Li, B.T., Smit, E.F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., et al. (2022) Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. New England Journal of Medicine, 386, 241-251. [Google Scholar] [CrossRef] [PubMed]
[38] Li, Z., Song, Z., Hong, W., Yang, N., Wang, Y., Jian, H., et al. (2024) SHR-A1811 (Antibody-Drug Conjugate) in Advanced HER2-Mutant Non-Small Cell Lung Cancer: A Multicenter, Open-Label, Phase 1/2 Study. Signal Transduction and Targeted Therapy, 9, Article No. 182. [Google Scholar] [CrossRef] [PubMed]
[39] Yao, H., Yan, M., Tong, Z., Wu, X., Ryu, M., Park, J.J., et al. (2024) Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2—Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2—Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial. Journal of Clinical Oncology, 42, 3453-3465. [Google Scholar] [CrossRef] [PubMed]
[40] Zhou, C., Yang, B., Sun, Y., Zhuang, W., Wang, L., Deng, T., et al. (2024) OA16.04 Preliminary Results from a FIH Study of GQ1005, a Novel HER2—ADC, in Patients with Advanced HER2-Expressing Solid Tumors and HER2-Mutated NSCLC. Journal of Thoracic Oncology, 19, S46. [Google Scholar] [CrossRef] 
[41] Yu, J., Fang, T., Yun, C., Liu, X. and Cai, X. (2022) Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Frontiers in Molecular Biosciences, 9, Article 847835. [Google Scholar] [CrossRef] [PubMed]
[42] Zhang, J., Liu, R., Gao, S., Li, W., Chen, Y., Meng, Y., et al. (2023) Phase I Study of A166, an Antibody—Drug Conjugate in Advanced HER2-Expressing Solid Tumours. NPJ Breast Cancer, 9, Article No. 28. [Google Scholar] [CrossRef] [PubMed]

为你推荐